Rodríguez-Ruiz et al. demonstrated in melanoma, breast, and colon cancer mouse models, that mice receiving RT (3 × 8 Gy) with anti-PD-1 and anti-4-1BB antibodies achieved faster and almost constant complete responses on distant non-irradiated tumor lesions [49]. Here, PDCD1 is linked to melanoma.